Global Genetic Testing for Cancer Risk Market Growth (Status and Outlook) 2023-2029

Global Genetic Testing for Cancer Risk Market Growth (Status and Outlook) 2023-2029

The global Genetic Testing for Cancer Risk market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Genetic Testing for Cancer Risk is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Genetic Testing for Cancer Risk is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Genetic Testing for Cancer Risk is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Genetic Testing for Cancer Risk players cover Myriad Genetics, Inc., Invitae Corporation, Illumina, Inc., Natera, Inc., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, CooperSurgical, Inc. and Agilent Technologies, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Cancer risk genetic testing looks for changes in someone's genes. Genetic changes can cause some cancers. Some cancers can run in families.

LPI (LP Information)' newest research report, the “Genetic Testing for Cancer Risk Industry Forecast” looks at past sales and reviews total world Genetic Testing for Cancer Risk sales in 2022, providing a comprehensive analysis by region and market sector of projected Genetic Testing for Cancer Risk sales for 2023 through 2029. With Genetic Testing for Cancer Risk sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Genetic Testing for Cancer Risk industry.

This Insight Report provides a comprehensive analysis of the global Genetic Testing for Cancer Risk landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Genetic Testing for Cancer Risk portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Genetic Testing for Cancer Risk market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Genetic Testing for Cancer Risk and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Genetic Testing for Cancer Risk.

This report presents a comprehensive overview, market shares, and growth opportunities of Genetic Testing for Cancer Risk market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Breast Cancer Risk Genetic Testing
Stomach Cancer Risk Gene Testing
Rectal Cancer Risk Genetic Testing
Others

Segmentation by application
Hospital
Clinic
Laboratory

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Myriad Genetics, Inc.
Invitae Corporation
Illumina, Inc.
Natera, Inc.
Laboratory Corporation of America Holdings
F. Hoffmann-La Roche Ltd
Quest Diagnostics Incorporated
CooperSurgical, Inc.
Agilent Technologies, Inc.
Thermo Fisher Scientific, Inc.
Twist Bioscience
Sophia Genetics
Fulgent Genetic, Inc.
Medgenome
CENTOGENE
CeGaT
LifeLabs Genetics
Ambry Genetics

Please note: The report will take approximately 2 business days to prepare and deliver.